Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0OJHEN
ADC Name	AVID-100
Synonyms	AVID 100; AVID100 Click to Show/Hide
Organization	Bristol Myers Squibb Co.; Formation Biologics
Drug Status	Phase 2
Indication	In total 5 Indication(s) Breast cancer [ICD11:2C60-2C65] Phase 2 Non-small cell lung cancer [ICD11:2C25] Phase 2 Squamous cell cancer [ICD11:2D60-2D61] Phase 2 Head and neck squamous carcinoma [ICD11:2C31] Terminated in phase 2 Triple negative breast cancer [ICD11:2C60-2C65] Terminated in phase 2
Structure
	3D MOL	2D MOL
Antibody Name	MAB100		Antibody Info
Antigen Name	Epidermal growth factor receptor (EGFR)		Antigen Info
Payload Name	Mertansine DM1		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)		Linker Info
Conjugate Type	Random conjugation through nucleophilic lysines.
Combination Type	Emtansine
Puchem SID	472419821

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT03094169	Phase 1/2	Phase 1a/2a dose escalation trial to determine safety, tolerance, MTD, and preliminary antineoplastic activity of AVID100, in patients with advanced or metastatic solid tumors of epithelial origin.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Patients with advanced or metastatic epithelial malignancies.
Administration Dosage	20, 40, 80, 120, 180, and 220 mg/m² every 3 weeks.
*Related Clinical Trial*
NCT Number	NCT03094169	Clinical Status	Phase 1/2
Clinical Description	Phase 1a/2a dose escalation trial to determine safety, tolerance, MTD, and preliminary antineoplastic activity of AVID100, in patients with advanced or metastatic solid tumors of epithelial origin.

References

Ref 1	First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors. J Clin Oncol. 2022 40:16_suppl, TPS3153-TPS3153.